Syngene International (BOM:539268) Debt-to-Equity : 0.13 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Syngene International Debt-to-Equity?

Syngene International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹901 Mil. Syngene International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹4,651 Mil. Syngene International's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹42,577 Mil. Syngene International's debt to equity for the quarter that ended in Mar. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Syngene International's Debt-to-Equity or its related term are showing as below:

BOM:539268' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13 Med: 0.34 Max: 0.87
Current: 0.13

During the past 13 years, the highest Debt-to-Equity Ratio of Syngene International was 0.87. The lowest was 0.13. And the median was 0.34.

BOM:539268's Debt-to-Equity is ranked better than
52.62% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs BOM:539268: 0.13

Syngene International Debt-to-Equity Historical Data

The historical data trend for Syngene International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syngene International Debt-to-Equity Chart

Syngene International Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.36

0.32

0.31

0.23

0.13

Syngene International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.23	N/A	0.21	N/A	0.13

Competitive Comparison of Syngene International's Debt-to-Equity

For the Biotechnology subindustry, Syngene International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syngene International's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syngene International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Syngene International's Debt-to-Equity falls into.

Syngene International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Syngene International's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(901	+	4651)	/	42577
	=	0.13

Syngene International's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(901	+	4651)	/	42577
	=	0.13

Syngene International (BOM:539268) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Syngene International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Syngene International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Syngene International (BOM:539268) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syngene International Ltd (BOM:539268) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SYNGENE:India

Address

Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099

Website

https://www.syngeneintl.com

Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.

Syngene International (BOM:539268) Headlines

No Headlines